Clinical value of the VEGF-C and VEGF-R3 in peripheral blood of patients with lung cancer

Abstract

Abstract:Objective To investigate the relationship between the expression of vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor receptor-3 (VEGF-R3) in peripheral blood of patients with lung cancer and the pathological characteristics, and to assess the ability to evaluate lymphatic and distant metastasis of the two marks. Methods VEGF-C and VEGF-R3 were detected by enzymelinked immunosorbent assay (ELISA) in 124 patients with lung cancer and 30 normal controls, and used to analyze the relationship with the pathological characteristics of lung cancer. Results The serum levels ［M(QR)］ of VEGF-C and VEGF-R3 in patients with lung cancer were 283.57 (120.70) pg/ml and 62.72 (43.02) ng/ml, significantly higher than the control whose VEGF-C and VEGF-R3 were 234.62 (129.20) ng/ml and 43.08 (17.07) pg/ml, respectively (Z=-2.840, P=0.005; Z=-3.834, P＜0.001). No correlation was found between the expression of VEGF-C and age, sex, primary tumor site, T stage (Z=-0.949, P=0.343; Z=-0.454, P=0.649; Z=-1.168, P=0.243; Z=-1.694, P=0. 090). But the expression of VEGF-C was significantly related with pathologic type, N stage and M stage (χ2=8.829, P=0.012; χ2=27.148, P＜0.001; Z=-2.221, P=0.026). However, the expression of VEGF-R3 was not correlated with age, sex, the site of the primary lesion, pathological type and T, N, M stage (Z=-0.558, P=0.577; Z=-0.599, P=0.549; Z=-0.703, P=0.482; χ2=1.166, P=0.558; Z=-0.680, P=0.496; χ2=0.353, P=0.950; Z=-1.523, P=0.128). Conclusion The expressions of VEGF-C and VEGF-R3 in patients with lung cancer are higher than those in normal control, and the expression of VEGF-C is related with pathologic type, N stage and M stage. The detection of VEGF-C in peripheral blood of lung cancer is expected to be an assistant marker for the evaluation of lymph node metastasis and blood metastasis, but VEGFR3 does not show its value.

Key words:Lung neoplasms,Vascular endothelial growth factor C,Vascular endothelial growth factor receptor-3,Neoplasm metastasis

Yao Yuejuan, Wang Yan, Wang Xing, Jing Jiexian. Clinical value of the VEGF-C and VEGF-R3 in peripheral blood of patients with lung cancer[J]. Journal of International Oncology, 2017, 44(4): 262-265.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics［J］.CA Cancer J Clin, 2015, 65(2): 87108. DOI: 10.3322/caac.21262. ［2］ Kazakydasan S, Rahman ZA, Ismail SM, et al. Prognostic significance of VEGFC in predicting micrometastasis and isolated tumour cells in N0 oral squamous cell carcinoma［J］. J Oral Pathol Med, 2016, In press. DOI: 10.1111/jop.12476. ［3］ Zong S, Li H, Shi Q, et al. Prognostic significance of VEGFC immunohistochemical expression in colorectal cancer: a metaanalysis［J］. Clin Chim Acta, 2016, 458: 106114. DOI: 10.1016/j.cca. 2016.04.037. ［4］ Lv XH, Liu BQ, Li XM, et al. Integrin α4 induces lymphangiogenesis and metastasis via upregulation of VEGFC in human colon cancer［J］. Anat Rec (Hoboken), 2016, 299(6): 741747. DOI: 10.1002/ar.23338. ［5］ Hisamatsu T, Mabuchi S, Sasano T, et al. The significance of lymphatic space invasion and its association with vascular endothelial growth factorC expression in ovarian cancer［J］. Clin Exp Metastasis, 2015, 32(8): 789798. DOI: 10.1007/s1058501597510. ［6］李少雷，郑庆锋，陈晋峰，等. 胸部CT联合VEGFC检测在NSCLC肺门和纵隔淋巴结转移诊断中的价值［J］. 中华医学杂志， 2012， 92（37）： 26242627. DOI: 10.3760/cma.j.issn.03762491.2012.37.009. ［7］郭嘉仲，孙启峰，丛波，等. Syk、VEGFC在非小细胞肺癌中表达及意义［J］. 中华医学杂志， 2013， 93（47）： 38013803. DOI: 10.3760/cma.j.issn.03762491.2013.47.021. ［8］ Cao R, Ji H, Yang Y, et al. Collaborative effects between the TNFαTNFR1macrophage axis and the VEGFCVEGFR3 signaling in lymphangiogenesis and metastasis［J］. Oncoimmunology, 2015, 4(3): e989777. ［9］ Yang WH, Chang AC, Wang SW, et al. Leptin promotes VEGFC production and induces lymphangiogenesis bysuppressing miR27b in human chondrosarcoma cells［J］. Sci Rep, 2016, 6: 28647. DOI: 10.1038/srep28647. ［10］陈重，魏立，陈晓，等. 血管内皮生长因子及受体在非小细胞肺癌的表达及其与淋巴转移的关系［J］. 中华实验外科杂志， 2013， 30（12）： 27192720. DOI: 10.3760/cam.j.issn.10019030.2013.12.086. ［11］ Su JL, Yang PC, Shih JY, et al. The VEGFC/Flt4 axis promotes invasion and metastasis of cancer cells［J］. Cancer Cell, 2006, 9(3): 209223. ［12］ Nagai N, Minami T. Emerging role of VEGFC in pathological angiogenesis［J］. EBioMedicine, 2015, 2(11): 15881589. DOI: 10.1016/j.ebiom.2015.11.006. ［13］ Singh NK, Kotla S, Kumar R, et al. Cyclic AMP response element binding protein mediates pathological retinal neovascularization via modulating DLL4NOTCH1 signaling［J］. EBioMedicine, 2015, 2(11): 17671784. DOI: 10.1016/j.ebiom.2015.09.042. ［14］曾洪生，郭其森，管燕，等. 非小细胞肺癌患者外周血淋巴结和肺癌组织中血管内皮生长因子C表达的相关性研究［J］. 中华肿瘤杂志， 2011， 33(7): 527528. DOI: 10.3760/cma.j.issn.02533766.2011.07.012.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[6]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[7]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[8]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin.Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(2): 117-121.
[9]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng.Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection[J]. Journal of International Oncology, 2023, 50(12): 711-716.
[10]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660.
[11]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[12]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[13]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun.Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model[J]. Journal of International Oncology, 2022, 49(9): 532-536.
[14]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying.Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses[J]. Journal of International Oncology, 2022, 49(8): 459-463.
[15]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.